News

GoLiver Therapeutics Wins Major Funding for Innovative Liver Treatment

GoLiver Therapeutics Wins Major Funding for Innovative Liver Treatment

GoLiver Therapeutics Secures Major Funding for GLTX-001

GoLiver Therapeutics is excited to share that it has recently triumphed in the France 2030 initiative, clinching an impressive €1.6 million in funding. This investment is aimed at propelling the development of its innovative biomedicine, GLTX-001, which seeks to provide a new treatment option for severe liver failure through the use of pluripotent stem cells.

Innovative Approach to Severe Liver Diseases

GoLiver Therapeutics is driven by a mission to tackle the escalating liver disease crisis worldwide. With over 800 million people suffering from chronic liver conditions, the company is leading the way in creating a biomedicine that could reduce the reliance on liver transplants, which are the only proven cure for patients facing end-stage liver disease.

The GOCLINICALS Project

The GOCLINICALS project marks a critical advancement in demonstrating the safety, efficacy, and tolerability of GLTX-001. This inventive treatment involves an injectable solution composed of allogeneic liver cells, which can be quickly prepared at the patient’s bedside. Preclinical evidence indicates that GLTX-001 significantly protects liver cells from damage and boosts the organ’s natural ability to regenerate.

Industrial Bioproduction Capabilities

A standout feature of GoLiver Therapeutics is its iMillenium™ manufacturing platform. This cutting-edge facility addresses the difficulties usually associated with producing the vast number of cells needed for effective cell therapy. By utilizing advanced pluripotent stem cell technology, it achieves remarkable yields and cost efficiency. Additionally, the infrastructure enables prompt market deployment, employing bioreactors that are already established in contract manufacturing organizations (CDMOs).

Commitment to Healthcare Innovation

Tuan Huy Nguyen, President of GoLiver Therapeutics, expressed his appreciation for the support from France 2030. He noted that this funding would significantly advance the company's efforts in developing its first advanced cell drug candidate. Nguyen stated, “GLTX-001 will be groundbreaking for patients with liver disease, as impressive preclinical results lay the groundwork for eventual clinical usage.”

Collaborative Efforts and Future Aspirations

To ensure the successful implementation of the GOCLINICALS project, GoLiver Therapeutics plans to leverage its longstanding collaborations with key partners, including the cell and gene therapy unit at Nantes University Hospital and the Paul-Brousse Hospital, one of France’s premier liver transplant centers. This collaboration is not only focused on liver disease but also aims to expand the application of their cell-based therapies to address various medical conditions, broadening their influence in the field of regenerative medicine.

Addressing a Global Health Challenge

Globally, liver failure is responsible for over two million deaths each year, and the supply of donor organs for transplantation is far from meeting demand. By harnessing the regenerative capabilities of patients' own liver cells, GoLiver Therapeutics aims to tackle this pressing medical need with high-quality bioproduced therapies.

About GoLiver Therapeutics

Founded in 2017 as a spin-off from Inserm and Nantes University, GoLiver Therapeutics is poised to become a leader in regenerative medicine by focusing on liver cell regeneration without relying on transplants. The company has garnered multiple accolades, including recognition from the European Union and various national awards, for its pioneering research in healthcare biotechnology.

Frequently Asked Questions

What is GLTX-001?

GLTX-001 is a biomedicine developed by GoLiver Therapeutics, consisting of an injectable solution made from frozen allogeneic liver cells designed to treat severe liver diseases.

How does the iMillenium™ platform benefit GoLiver Therapeutics?

The iMillenium™ platform provides efficient production capabilities, allowing for the manufacture of billions of liver cells with high yield and cost-effectiveness, which accelerates clinical trials.

What is the GOCLINICALS project?

The GOCLINICALS project aims to clinically assess and confirm the safety and efficacy of GLTX-001 in patients with severe liver failure.

Who are GoLiver Therapeutics’ key partners?

Key partnerships include collaborations with the cell and gene therapy unit at Nantes University Hospital and the Paul-Brousse Hospital, both of which enhance research and clinical development efforts.

What are the future aspirations of GoLiver Therapeutics?

GoLiver Therapeutics plans to diversify its therapeutic offerings and expand innovations in regenerative medicine beyond liver diseases, addressing a range of medical challenges.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 42

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 78

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 136

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 68

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 80

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 160

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Investors in Metagenomi Class Action

Updated Category News Views 103

Key Deadline for Metagenomi Investors As investors in Metagenomi, Inc. keep a close watch, an important deadline is approaching. The time to file a lead plaintiff motion in the class action lawsuit is set for November 25, 2024. This action is vital for those who purchased or acquired Metagenomi securities, specifically those linked to the company’s latest initial public...

Continue Reading
Structure Therapeutics Engages with Investors at Key Conferences

Updated Category News Views 78

Structure Therapeutics Engages with Investors at Key Conferences Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company, is gearing up to participate in important investor conferences this September. The company is dedicated to developing innovative oral small molecule therapeutics aimed at treating metabolic and cardiopulmonary...

Continue Reading
OmaSp Reports Solid Financial Performance with Growth Prospects

Updated Category News Views 156

OmaSp's Strong Financial Performance and Future Outlook OMA SAVINGS BANK PLC has recently released its financial statements for the year ending December 31, 2024, showing promising results and projections for continued growth. Known as OmaSp, the bank reported a noteworthy fourth quarter, aligning with the expectations set forth at the beginning of the year, and a solid...

Continue Reading
Unveiling the Reagan National Economic Forum for Future Growth

Updated Category News Views 485

Reagan National Economic Forum Set to Inspire Economic Solutions The Ronald Reagan Presidential Foundation and Institute is gearing up for a transformative inaugural economic summit with leading figures from the business and economic policy landscapes to take place in late May 2025. About the Forum’s Objectives The Reagan National Economic Forum (RNEF) aims to provide a...

Continue Reading
Experience the Vibrant Latin Business Networking Event of 2025

Updated Category News Views 279

Celebrating the Latino Business Community Prepare yourself for an unforgettable networking event dedicated to the Latino business community, brought to you by Latin Biz Today and Mercy University. The Spectrum of Success event promises a night filled with excitement, learning, and cultural experiences that will leave a lasting impression on everyone involved. A Night of...

Continue Reading